文献速递骨肿瘤关节外科

股骨远端合并胫骨近端复合假体置换的假体生存与保肢率

Implant survival and limb salvage rates after combined proximal tibial and distal femoral endoprosthetic replacement.
PubMed 文献 · Bone Joint J · 2026-06-01

结果显示5年和10年无翻修假体生存率分别为77%和61%,5年和10年保肢率分别为81%和69%;长期保肢失败的主要原因为感染。

要点

  • 复合假体置换可作为膝周肿瘤切除后初次或翻修情形下的可行保肢选择。
  • 5年和10年无翻修假体生存率分别为77%和61%。
  • 长期保肢失败的首要原因为感染,需谨慎选择患者并做好术前讨论。

核心结论

  • 膝周肿瘤切除后复合假体置换在初次或翻修情形下是可行的保肢选择,但中长期存在再手术风险。
  • 长期保肢失败的首要原因为感染。
  • 建议谨慎选择患者并在术前充分讨论后再考虑复合重建。

研究设计与样本

  • 共34例(男21例、女13例),平均年龄32岁(14至66岁),中位随访12.6年(IQR 3至14)。
  • 主要结局为无翻修假体生存率,次要结局为无截肢生存率、MSTS评分及伸膝迟滞。
  • 原发8例、翻修26例。

主要发现

  • 肿瘤诊断包括骨肉瘤26例、尤文肉瘤5例,骨巨细胞瘤、梭形细胞肉瘤、软骨肉瘤、滑膜肉瘤各1例。
  • 5年和10年无翻修假体生存率分别为77%(95%CI 63至94%)和61%(95%CI 45至83%)(Kaplan-Meier)。
  • 5年和10年保肢率分别为81%(95%CI 68至96%)和69%(95%CI 54至89%)。
  • 截骨长度及假体与柄比值对翻修率无影响。
  • 30例有活动度结果、20例有MSTS评分,平均伸膝迟滞25°(10°至50°),平均MSTS评分53%(27%至67%)。

关键数值与推荐

  • 5年无翻修假体生存率77%(95%CI 63至94%),10年61%(95%CI 45至83%)。
  • 5年保肢率81%(95%CI 68至96%),10年69%(95%CI 54至89%)。
  • 平均伸膝迟滞25°(10°至50°),平均MSTS评分53%(27%至67%)。

临床怎么用

  • 对膝周原发骨肿瘤需同时切除股骨远端与胫骨近端的患者,可将复合假体重建作为保肢选项之一。
  • 术前应向患者说明中长期再手术风险及感染导致保肢失败的可能,并谨慎筛选患者。

局限性

  • 为单中心回顾性研究,样本量34例,部分结局(活动度30例、MSTS评分20例)数据不完整。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS: Combined endoprosthetic replacement of the ipsilateral distal femur and proximal tibia is rarely performed. It is usually undertaken to achieve limb salvage after resection of primary bone tumours around the knee. This study aims to determine the viability of 'composite' endoprosthetic reconstruction around the knee, and report implant survival and limb salvage rates. METHODS: A retrospective review of a prospectively maintained departmental database was undertaken to identify patients who had undergone composite endoprosthetic reconstruction around the knee. The primary outcome of interest was revision-free implant survival. Secondary outcomes were amputation-free survival, the Musculoskeletal Tumor Society (MSTS) score, and extensor lag. A total of 34 patients (21 male and 13 female) with a mean age of 32 years (14 to 66) underwent surgery between January 1997 and November 2024, and were followed up for a median interval of 12.6 years (IQR 3 to 14). RESULTS: The oncological diagnoses were osteosarcoma (n = 26), Ewing's sarcoma (n = 5), and one each of giant cell tumour of bone, spindle cell sarcoma, chondrosarcoma, and synovial sarcoma. Of the eight primary and 26 revision cases, the pooled five- and ten-year revision-free implant survival rates were 77% (95% CI 63 to 94%) and 61% (95% CI 45 to 83), respectively (Kaplan-Meier). Resection length and construct:stem ratio had no impact on revision rate. Limb salvage at five and ten years was 81% (95% CI 68 to 96) and 69% (95% CI 54 to 89), respectively. Range of motion outcomes were available in 30 patients and MSTS scores in 20 patients. The mean extensor lag was 25° (10° to 50°) and the mean MSTS score was 53% (27% to 67%). CONCLUSION: Composite endoprosthetic reconstruction around the knee after tumour resection is a viable limb salvage option in the primary or revision setting; however, it does carry a risk of reoperation in the medium and long term. The leading reason for failed limb salvage in the long term is infection. We recommend careful patient selection and preoperative discussion before contemplating composite reconstruction.

来源:Bone Joint J,查看原文。版权归原作者所有。

引用

  1. Baird CAE, Archer JE, Green NM, et al. Implant survival and limb salvage rates after combined proximal tibial and distal femoral endoprosthetic replacement. Bone Joint J. 2026. PMID: 42219182. doi:10.1302/0301-620X.108B6.BJJ-2025-1470.R1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。